Crizotinib is a small-molecule inhibitor targeting c-Met, ALK, and ROS1 tyrosine kinases that is approved for NSCLC harboring EML4-ALK rearrangements [67]. This evidence concerns the gene ALK and non-small cell lung carcinoma.